Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol

Research output: Contribution to journalJournal articleResearch

  1. Outcomes reported on the management of COPD exacerbations: a systematic survey of randomised controlled trials

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Fast-track pneumonia pathway focusing on early progressive mobilisation: a clinical feasibility study

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Feasibility of portable continuous laryngoscopy during exercise testing

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Investigating Intestinal Glucagon after Roux-en-Y Gastric Bypass Surgery

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Multiple Fractures and Impaired Bone Fracture Healing in a Patient with Pycnodysostosis and Hypophosphatasia

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Non-alcoholic fatty liver disease alters expression of genes governing hepatic nitrogen conversion

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Assessment of acute bone loading in humans using [18F]NaF PET/MRI

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
Antipsychotic medication is widely associated with dysmetabolism including obesity and type 2 diabetes, cardiovascular-related diseases and early death. Obesity is considered the single most important risk factor for cardiovascular morbidity and mortality. Interventions against antipsychotic-associated obesity are limited and insufficient. Glucagon-like peptide-1 (GLP-1) receptor agonists are approved for the treatment of type 2 diabetes, but their bodyweight-lowering effects have also been recognised in patients with non-diabetes. The primary endpoint of this trial is weight loss after 3 months of treatment with a GLP-1 receptor agonist (exenatide once weekly) in patients with non-diabetic schizophrenia with antipsychotic-associated obesity. Secondary endpoints include physiological and metabolic measurements, various psychopathological and cognitive measures, and structural and functional brain MRI.
Original languageEnglish
JournalB M J Open
Volume4
Issue number1
Pages (from-to)e004158
ISSN2044-6055
DOIs
Publication statusPublished - 2014

ID: 42313686